Quantitative dynamic contrast-enhanced MRI (DCE-MRI) provides the next generation of markers of disease status and drug action. Bioxydyn and Imorphics offer a one-stop world-class service which combines site training, automated 3D lesion identification, automated RAMRIS-style scoring and quantification of microvascular status in inflammation.
We are experts and world-leaders in providing three-dimensional DCE-MRI - a technique that provides meaningful and specific imaging biomarkers of focal inflammation and damage. Armed with years of well established and sound scientific methodology, we offer robust imaging capabilities that are second to none. Our automated methods combined with hands-on experience can revolutionise clinical studies in RA.
Quantitative imaging measurements of the physiological effects of novel therapeutics is increasingly integral to clinical trials. Whether you are interested in looking at joint perfusion, vessel permeability, inflammation or bone morphology we have a range of robust quantitative image technologies for use in your study.
We are accomplished providers of advanced MR imaging services to the clinical trials market. We understand that in order to achieve timely delivery of compelling results using state-of-the-art imaging you need a partner who can offer a comprehensive skill set that can be tailored for your needs. That is why our expertise covers all stages of the imaging pipeline from biomarker identification and protocol development through site qualification and training, medical device quality software development, image transfer and processing to statistical analysis, reporting and results interpretation.
We can provide expert scientific study input from the onset. We can advise on the best imaging technologies to use, the relevant imaging biomarkers and sample sizes to meet study goals.
We develop novel 3D measures for your study which may prove even more responsive than standard and current semi-quantitative measures in RA.
Rigorous automated algorithms produce quantitative imaging biomarkers of joint disease status. Our high quality data processing ensure the highest quality imaging endpoints are produced and delivered to the client.
Early decision making about potential drug efficacy in your hands. We are with you to help you - quality, robust and powerful decision making tools.
Image: Manchester from the Sky, 2008 B) Daniel Nisbet CC BY 2.0